At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
In conjunction with the launch of Dymista® in Malaysia, Mylan convened a symposium which saw distinguished speakers addressing the allergic rhinitis (AR) landscape in the country and the latest developments in treatment options.
Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 20181011035429
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
Type 2 diabetes mellitus (T2DM) is associated with substantial risks of cardiovascular disease (CVD) risk and overall mortality, despite the advances in treatment options.1 Recently, MIMS Doctor spoke to Dato’ Sri Dr Azhari Rosman, a Senior Consultant Cardiologist at the National Heart Institute, to provide an update on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in managing CV risk associated with T2DM, and discuss the results of the recently published Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL) 2 study. Here are the highlights from the interview.
The “Stay healthy: You call the shots” meeting, hosted by Sanofi Pasteur, was held at Thistle Port Dickson. During the meeting, Dr Ho Bee Kiau, Dr Leong Chee Loon and Dr Salehuddin Samsudin shared their insights into the role of influenza vaccination in reducing antimicrobial resistance (AMR), complications in high-risk patient populations, and dispelling vaccination myths among patients.
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
Patients with mild hypertension who are at low risk for cardiovascular disease (CVD) do not appear to derive mortality or CVD benefit from antihypertensive treatments, raising questions on the need for treatment in this population, according to a recent study from England.
A personalized computerized neurofeedback intervention for training attention and memory shows potential in cognitive training for healthy elderly men, who improved in cognitive performance after the training, although no significant improvements were seen in the overall study population.
Higher exposure to ticagrelor following myocardial infarction does not appear to contribute to an increased risk of intracranial haemorrhage, which is associated with age and prior cardiovascular morbidities, according to a study.